Important progress in product development – simultaneous staining in the same section, with high degree of detail

Lumito is developing a novel method for high-contrast imaging without background signal. The first application is developed for tissue diagnostics and digital pathology. In order to visualize cells containing Her2, which is a common marker in breast cancer diagnostics, Lumito is now presenting new images of breast tissues stained with the Company's Her2-UCNP reagent.

Lumito's technology makes it possible to stain tissue with nanoparticle-based reagents, and thus to create images with the company’s proprietary analysis instrument. Two of the major advantages are the ability to create imaging with high contrast and detail, and the ability to use both Lumito's reagent and traditional reagents to stain the same tissue section.

The images show a degree of detail comparable to the one achieved with traditional staining methods. The advantage of the imaging created with Lumito's technology is that only the signals from the intended markers are present – in this case, the breast cancer marker Her2.

-     When you examine the Her2 imaging based on Lumito's technology, you can readily understand the opportunities it opens for pathologists when they are able to see only the tissue they are interested in. The technology further opens the door for image processing, which may help facilitate automated diagnostics in the future, says Stefan Nilsson, CEO of Lumito.

Lumito is also publishing cell imagery where UCNP staining and traditional H&E staining have been combined in the same section. The user may then choose to perform analysis on the images separately, or on the aggregate image
 

Images and captions:

Figur 1 Jmfrelse mellan Lumitos UCNPinfrgning och standard immunohistokemisk DABinfrgning  I bild A r brstvvnad infrgad med Her2UCNPreagens fr att visualisera celler med frekomst av Her2 en vanlig markr vid diagnos av brstcancer           Bild B visar infrgning i samma vvnadsprov som i bild A men med standard DABinfrgning Bde bild A och bild B visar jmfrbar detaljeringsniv men bde bakgrundssignal och autofluorescens r eliminerade i Lumitos UCNPbaserade infrgning Eliminering av all ovsentlig information frn bakgrundssignal och autofluorescens ger vsentligt bttre frutsttningar fr automatiserad analys baserat p t ex AIalgoritmer

Figure 1. Comparison between Lumito's UCNP staining and the standard immunohistochemical DAB-based staining. In image A, the breast tissue has been stained with Her2-UCNP reagent, in order to visualize cells containing Her2, which is a common marker in breast cancer diagnostics.
Image B shows staining in the same tissue sample as in image A, but performed with the standard DAB-based method. Images A and B show a comparable level of detail, but both background signal and autofluorescence are eliminated in Lumito's UCNP-based staining.  Eliminating all noise from background signal and autofluorescence improves the conditions for automated analysis based on for example AI algorithms significantly.

Figur 2 Kombinerad UCNPinfrgning och HEinfrgning i samma cellsnitt Lumitos teknologi stdjer bde UCNPinfrgning och HEinfrgning i samma vvnadsprov Anvndaren kan sedan vlja att analysera bda bilderna var fr sig eller i en sammanslagen bild Bild A visar UCNPbaserad Her2infrgning av BT 474 som r en brstcancercellinje I bild B visas standardiserad HEinfrgning av samma snitt I bild C visas den sammanslagna bilden

Figure 2. Combined UCNP and H&E staining in the same cell section.
Lumito's technology supports the performance of both UCNP and H&E staining in the same tissue sample. The user may then choose to perform analysis on the images separately, or on the aggregate image. Image A shows a UCNP-based Her2 stain of BT 474, a breast cancer cell line. In image B, the same section is shown with a standard H&E stain. Image C shows the aggregate image. The user may choose to perform analysis on both images separately, or, to improve accuracy and diagnostic reliability, on the aggregate image as shown here. (The identified cancer cells are visible in yellow).

Images are available for download: https://news.cision.com/se/lumito

Please contact:

Stefan Nilsson, CEO of Lumito

Telephone: +4676-778 59 05

E-mail:sn@lumito.se

Lumito in brief
Lumito is specialised in research and development of imaging technologies for medical applications. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito´s IPR covers imaging with high quality of for instance tissue samples, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology. Lumito has an agreement with TTP plc (The Technology Partnership) in Cambridge, UK, regarding development of instruments and staining reagents. Lumito’s share Lumito and warrant Lumito TO1 are traded at the NGM Nordic MTF marketplace. www.lumito.se

Tags:

Subscribe

Media

Media

Quick facts

Lumito is developing a novel method for high-contrast imaging without background signal. The first application is developed for tissue diagnostics and digital pathology. In order to visualize cells containing Her2, which is a common marker in breast cancer diagnostics, Lumito is now presenting new images of breast tissues stained with the Company's Her2-UCNP reagent.
Tweet this

Quotes

When you examine the Her2 imaging based on Lumito's technology, you can readily understand the opportunities it opens for pathologists when they are able to see only the tissue they are interested in. The technology further opens the door for image processing, which may help facilitate automated diagnostics in the future.
Stefan Nilsson, CEO Lumito